SEC Form 4 · accession 0001127602-16-068059
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Madigan
Director
Period of report
Nov 18, 2016
Accepted (ET)
Nov 22, 2016 · 2:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 18, 2016 | M | 105,000 | $20.705 | A | 121,761 | D | |
| Common StockF2 | Nov 18, 2016 | S | 105,000 | $74.8577 | D | 16,761 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $20.705 | Nov 18, 2016 | M | 105,000 | D | — | May 9, 2017 | Common Stock | 105,000 | 0 | D |
Explanation of responses
- F1Options vested in full on May 9, 2007, the date of grant.
- F2Sale prices reported for the transactions reported here range from $74.55 to $75.18. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.